A Case of Myelofibrosis Masquerading as Pericarditis, the Role of Hematologic Evaluation in Systemic Inflammation: A Case Report
Abstract
This case report describes a middle-aged female with untreated hypertension who was released from the hospital with signs and symptoms of sharp pleuritic chest pain, with a concern for a cardiac issue. Following the concern for a cardiac diagnosis, diagnostic testing determined profound ST elevations across the ECG, severe anemia (hemoglobin 9.6 g/dL), and inflammatory activity (ESR 93 mm/hr, CRP 77.7 mg/L), with high LDH (2185 U/L). There was evidence on imaging of left atrial enlargement, hepatosplenomegaly, liver lesions, and mineralized bone changes, with myelofibrosis (MF) confirmed through marrow biopsy showing marrow fibrosis and atypical megakaryocytes. This case illustrates the diagnostic considerations of MF, which can present with various differential diagnoses. Treatment of the patient consisted of managing symptoms with aspirin; the possible options of treatment included longterm therapy with a JAK2 inhibitor or stem cell transplant. This case underscores the importance of considering MF in patients with unexplained cytopenias, splenomegaly,
and systemic inflammation.
[2] Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. https://doi.org/10.1182/blood-2016-03-643544
[3] Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative
classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-69. https://doi.org/10.1038/s41375-018-0077-1
[4] Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014 Jan 29;7:89-101. https://doi.org/10.2147/ijgm.s51800
[5] Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016
Dec;91(12):1262-71. https://doi.org/10.1002/ajh.24592
[6] Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Blood. 2017 Feb 9;129(6):667-79. https://doi.org/10.1182/blood-2016-10-695940
| Files | ||
| Issue | Vol 10 No 3 (2025): May-June | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/crcp.v10i3.20307 | |
| Keywords | ||
| Myelofibrosis Myeloproliferative neoplasm Extramedullary hematopoiesis Bone marrow fibrosis Pericarditis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
